Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of myocardial infarction among Tunisian male patients

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 420-424

  Kallel, Amani ^a   Abdessalem, Salem ^a   Sédiri, Yosra ^a   Mourali, Mohamed Sami ^a   Feki, Moncef ^a   Mechmeche, Rachid ^a   Jemaa, Riadh ^a   Kaabachi, Naziha ^a  

^a LA RABTA HOSPITAL   (Tunisia)

Author keywords

CCR2; CCR5; Chemokine receptors; Myocardial infarction; Polymorphisms

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NULL ALLELE; OBESITY; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; TUNISIA;

ADULT; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, CCR2; RECEPTORS, CCR5; RISK FACTORS; TUNISIA;

EID: 84858381868     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.004     Document Type: Article

References (35)

1. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:1876-1890.
2. Lesnik P., Haskell C.A., Charo I. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003, 111:333-340.
3. Gonzalez P., Alvarez R., Batalla A., et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001, 2:191-195.
4. Murphy P.M. Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine Growth Factor Rev 1996, 7:47-64.
5. Schecter A.D., Calderon T.M., Berman A.B., et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000, 275:5466-5471.
6. Murphy P.M., Baggiolini M., Charo I.F., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
7. Lee B., Doranz B.J., Rana S., et al. Influence of the CCR2-V641 polymorphism on human immunodeficiency virus type 1 coreptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998, 72:7450-7458.
8. Dean M., Carrington M., Winkler C., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
9. Gharagozloo M., Doroudchi M., Farjadian S., et al. The frequency of CCR5δ32 and CCR264I in southern Iranian Normal population. Immunol Lett 2005, 96:277-281.
10. Ortlepp J.R., Vesper K., Mevissen V., et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med 2003, 81:363-367.
11. Petrkova J., Cermakova Z., Drabek J., et al. CC-chemokine receptor (CCR) 2 polymorphism in Cezek patients with myocardial infarction. Immunol Lett 2003, 88:53-55.
12. Simeoni E., Winkelmann B.R., Hofmann M.M., et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J 2004, 25:1438-1446.
13. Karaali Z.E., Sozen S., Yurdum M., et al. Effect of genetic variants of chemokine receptors on the development of myocardial infarction in Turkish population. Mol Biol Rep 2010, 37:3615-3619.
14. Physical status: the use and interpretation of anthropometry. WHO Technical Report Series 1995, vol. 854:321-344. World Health Organisation, WHO, Geneva.
15. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultra centrifuge. Clin Chem 1972, 18:499-502.
16. Marcadet A., O'Connel P., Cohen D. Standardized Southern blot workshop techniques. Histocompatibility testing 1987, 587-590. Springer, New York. B. Dupont (Ed.).
17. Tregouet D.A., Tiret L. Cox proportional hazards survival regression in haplotype-based association analysis using the Stochastic-EM algorithm. Eur J Hum Genet 2004, 12:971-974.
18. Candore G., Vasto S., Colonna-Romano G., et al. Cytokine gene polymorphisms and atherosclerosis. Cytokine gene polymorphisms in multifactorial conditions 2006, 363-378. Florida CRC press. K. Vandenbroeck (Ed.).
19. Valdes A.M., Wolfe M.L., O'Brien E.J., et al. Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler Thromb Vasc Biol 2002, 22:1924-1928.
20. Szalai C., Duba J., Prohaszka Z., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis 2001, 158:233-239.
21. Pai J.K., Kraft P., Cannuscio C.C., et al. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and-5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 2006, 186:132-139.
22. Bjarnadottir K., Eiriksdottir G., Aspelund T., et al. Examination of genetic effects of polymorphisms in the MCP-1 and CCR2 genes on MI in the Icelandic population. Atherosclerosis 2006, 188:341-346.
23. Dow D.J., McMahon A.D., Gray I.C., et al. CCR2 and coronary artery disease: a Woscops substudy. BMC Research Notes 2010, vol. 3:31.
24. Apostolakis S., Baritaki S., Kochiadakis G.E., et al. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 2007, 119:63-71.
25. Cha S.H., Lee J.K., Lee J.Y., et al. Association of CCR2 polymorphisms with the number of closed coronary artery vessels in coronary artery disease. Clin Chim Acta 2007, 382:129-133.
26. Balistreri C.R., Candore G., Caruso M., et al. Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity. Haematologica 2008, 93:637-638.
27. Afzal A.R., Kiechl S., Daryani Y.P., et al. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke 2008, 39:1972-1978.
28. Ghilardi G., Biondi M.L., Turri O., et al. Genetic control of chemokines in severe human internal carotid artery stenosis. Cytokine 2008, 41:24-28.
29. Sharda S., Gilmour A., Harris V., et al. Chemokine receptor 5 (CCR5) deletion polymorphism in North Indian patients with coronary artery disease. Int J Cardiol 2008, 124:254-258.
30. Ghilardi G., Biondi M.L., Battaglioli L., et al. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. J Vasc Surg 2004, 40:995-1000.
31. Liu R., Paxton W.A., Choe S., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-infection. Cell 1996, 86:367-377.
32. Martinson J.J., Chapman N.H., Rees D.C., et al. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997, 16:100-103.
33. Raport C.J., Gosling J., Schweickart V.L., et al. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996, 271:17161-17166.
34. Schecter A.D., Calderon T.M., Berman A.B., et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000, 275:5466-5471.
35. Wilcox J.N., Nelken N.A., Coughlin S.R., et al. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1994, (Suppl 1):S10-S13.